Business
BioNexus owns Malaysian subsidiaries focused on industrial chemical raw materials and blood-based genomic screening services.
BioNexus revenue fell and losses widened, even though cash burn improved and the forensic screens were clean.
The read at a glance✓ Audited against SEC data
- Business mix — Industrial chemicals plus genomic screeningNote
- Revenue — $7.4M, down 21.9%Watch
- Losses — Net loss widened to $3.0MWatch
- Cash — Free cash flow improved to -$1.9MOK
- SBC — Stock comp up 463.7%Watch
- Insiders — 0 purchases / 0 salesNote
- Accounting — Altman-Z safe; Beneish-M and earnings-quality safeOK
Leadership changes
From BioNexus Gene Lab Corp's own filings, the day they're filed.
- Chong Set Fui · Chief Financial Officer · appointmenteff. 2025-06-17
- Jook Yuen Low · director · appointmenteff. 2024-11-05
- Wei Li Leong · Chief Financial Officer · departureeff. 2023-10-30
Latest filings
- 10-Q · Quarterly report2026-08-14
- 8-K · Company announcement2026-07-28
- 8-K · Company announcement2026-06-05
- 10-Q · Quarterly report2026-05-15
- 10-K · Annual report2026-04-14
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about BioNexus Gene Lab Corp, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.